Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis of Results from Phase 2/3 Studies
Articolo
Data di Pubblicazione:
2020
Abstract:
Ustekinumab is currently approved globally in Crohn's disease (CD) and psoriatic diseases. Recent phase 3 data demonstrate safety/efficacy in ulcerative colitis (UC). Crohn's disease and UC phase 3 programs had similar study designs, facilitating integrated safety analyses.
Tipologia CRIS:
1.1 Articolo in rivista
Keywords:
inflammatory bowel disease; safety; ustekinumab
Elenco autori:
Sandborn, William J; Feagan, Brian G; Danese, Silvio; O'Brien, Christopher D; Ott, Elyssa; Marano, Colleen; Baker, Thomas; Zhou, Yiying; Volger, Sheri; Tikhonov, Ilia; Gasink, Christopher; Sands, Bruce E; Ghosh, Subrata
Link alla scheda completa:
Pubblicato in: